Free Trial

Y-mAbs Therapeutics (YMAB) Stock Forecast & Price Target

$11.59
-0.11 (-0.94%)
(As of 07/19/2024 ET)

Y-mAbs Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 7 Wall Street analysts who have issued ratings for Y-mAbs Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 7 analysts, 2 have given a sell rating, and 5 have given a buy rating for YMAB.

Consensus Price Target

$17.86
54.07% Upside
High Forecast$26.00
Average Forecast$17.86
Low Forecast$5.00

According to the 7 analysts' twelve-month price targets for Y-mAbs Therapeutics, the average price target is $17.86. The highest price target for YMAB is $26.00, while the lowest price target for YMAB is $5.00. The average price target represents a forecasted upside of 54.07% from the current price of $11.59.

TypeCurrent Forecast
7/22/23 to 7/21/24
1 Month Ago
6/22/23 to 6/21/24
3 Months Ago
4/23/23 to 4/22/24
1 Year Ago
7/22/22 to 7/22/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
5 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$17.86$17.33$16.57$12.00
Forecasted Upside54.07% Upside37.51% Upside27.10% Upside90.48% Upside
Get Y-mAbs Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

YMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

YMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Y-mAbs Therapeutics Stock vs. The Competition

TypeY-mAbs TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.43
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside54.07% Upside3,241.48% Upside10.06% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/28/2024Truist Financial
1 of 5 stars
N. Germino
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00+70.32%
5/13/2024HC Wainwright
3 of 5 stars
 Boost TargetBuy ➝ Buy$21.00 ➝ $22.00+83.03%
3/4/2024Canaccord Genuity Group
1 of 5 stars
 Boost TargetBuy ➝ Buy$22.00 ➝ $26.00+37.42%
3/4/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$16.00 ➝ $26.00+39.11%
2/12/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$12.00 ➝ $18.00+25.35%
8/22/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$8.00 ➝ $7.00+14.94%
8/14/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$7.00 ➝ $5.00-9.91%
5/15/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$6.00 ➝ $12.00+33.48%
4/3/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
1/5/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
10/31/2022Kempen & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:53 PM ET.

YMAB Forecast - Frequently Asked Questions

What is Y-mAbs Therapeutics' forecast for 2024?

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Y-mAbs Therapeutics is $17.86, with a high forecast of $26.00 and a low forecast of $5.00.

Should I buy or sell Y-mAbs Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 sell ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares.

Does Y-mAbs Therapeutics's stock price have much upside?

According to analysts, Y-mAbs Therapeutics's stock has a predicted upside of 42.11% based on their 12-month stock forecasts.

What analysts cover Y-mAbs Therapeutics?

Y-mAbs Therapeutics has been rated by research analysts at HC Wainwright, and Truist Financial in the past 90 days.

Do Wall Street analysts like Y-mAbs Therapeutics more than its competitors?

Analysts like Y-mAbs Therapeutics less than other "medical" companies. The consensus rating for Y-mAbs Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how YMAB compares to other companies.


This page (NASDAQ:YMAB) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners